
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
PAREXEL International Corporation announced a collaboration with CHA Medical Group to enhance early phase clinical development in Korea. The alliance is designed to provide biopharmaceutical companies with services that leverage PAREXEL’s clinical research and regulatory expertise with CHA’s experience conducting early phase studies in Korea.
Read the full release






